Calcium, magnesium, potassium and sodium oxybates (Xywav) vs Sodium Oxybate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Narcolepsy

Shared mechanism: GABA-B receptor · full Narcolepsy pipeline

Calcium, magnesium, potassium and sodium oxybates (Xywav)

Marketed by Jazz Pharmaceuticals

Approved in Narcolepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07625280 (registry estimate)

No aligned efficacy figure on record for this race.

Sodium Oxybate

Marketed by Jazz Pharmaceuticals

Approved in Narcolepsysmall molecule
Partial signal

NCT02221869 · Phase 3 · completed

Double-blind, placebo-controlled randomized-withdrawal design with a clinical primary endpoint (change in weekly cataplexy attacks), clearly met (p<0.0001 in the publication). Placebo randomization was stopped early by plan after an interim analysis showed efficacy, so 63 children were randomized against a planned 70, and the reported sample-size estimate was for a different form of the endpoint (percentage change) rather than the change analysed.

Next expected readout: June 2027 · NCT06809803 (registry estimate)

Reported efficacy

Change in Weekly Number of Cataplexy Attacks (From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)): Change in weekly cataplexy attacks in the 2-week randomized-withdrawal period: placebo median increase 12.7 vs sodium oxybate 0.3 attacks per week, p<0.0001 (Plazzi et al., Lancet Child Adolesc Health 2018). (met)

Result source: NCT02221869

Results for Narcolepsy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Calcium, magnesium, potassium and sodium oxybates (Xywav): registry results are on file for Narcolepsy, but their comparison mappings are not yet available.

Sodium Oxybate: registry results are on file for Narcolepsy, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Calcium, magnesium, potassium and sodium oxybates (Xywav)'s landscape · Sodium Oxybate's landscape